Wockhardt Limited

NSE WOCKPHARMA.NS

Wockhardt Limited Free Cash Flow Per Share for the year ending March 31, 2024: USD 0.00

Wockhardt Limited Free Cash Flow Per Share is USD 0.00 for the year ending March 31, 2024, a 105.26% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Wockhardt Limited Free Cash Flow Per Share for the year ending March 31, 2023 was USD -0.05, a -121.54% change year over year.
Wockhardt Limited Free Cash Flow Per Share for the year ending March 31, 2022 was USD 0.22, a 142.65% change year over year.
Wockhardt Limited Free Cash Flow Per Share for the year ending March 31, 2021 was USD -0.51, a -197.81% change year over year.
Wockhardt Limited Free Cash Flow Per Share for the year ending March 31, 2020 was USD 0.53, a 579.81% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NSE: WOCKPHARMA.NS

Wockhardt Limited

CEO	Dr. Habil Fakhruddin Khorakiwala
IPO Date	July 1, 2002
Location	India
Headquarters	Wockhardt Towers
Employees	2,386
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.

Key trends

Past 5 years